CJC-1295 is one of the most common growth hormone secretagogue peptides discussed in research and anti-aging circles, often paired with a second peptide like ipamorelin. Understanding what it actually is clarifies a lot of the confusion around it.

What It Is

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the natural hormone that signals the pituitary gland to release growth hormone. It comes in two distinct versions that get conflated constantly: CJC-1295 without DAC (also sold as Mod GRF 1-29), which has a short half-life of minutes, and CJC-1295 with DAC (Drug Affinity Complex), chemically modified to bind albumin and extend its half-life to several days.

Regulatory Status

CJC-1295 is not FDA-approved as a drug and is not on the FDA's approved list for pharmacy compounding. It's sold as a research chemical, and any use outside a laboratory research setting falls outside its labeled purpose.

What the Research Shows

Early-stage human studies of CJC-1295 (with DAC) in the mid-2000s did examine its effects on growth hormone and IGF-1 levels in healthy adults, showing measurable increases, but this research was limited in scope and was not pursued through the larger trial process required for drug approval. Most other available research is preclinical, and there is no large-scale, modern clinical trial establishing safety or efficacy for the doses and protocols commonly promoted online.

Safety Considerations

Sustained elevation of growth hormone and IGF-1 raises legitimate theoretical concerns discussed in the broader endocrinology literature, including effects on insulin sensitivity and, over very long-term use, theoretical concerns about tissue growth, though these haven't been specifically studied for CJC-1295 protocols at the doses and durations commonly used outside clinical supervision.

The Bottom Line

CJC-1295 has more early-stage human data behind it than compounds like BPC-157, but that data is still far short of what would be needed to establish a proven safety and efficacy profile, and the two variants are different enough pharmacologically that research on one shouldn't be assumed to apply to the other.

Why the DAC Distinction Gets Lost in Marketing

Because "CJC-1295" is used as a catch-all name for both variants in much consumer-facing marketing, buyers don't always know which version, and which very different half-life and dosing implication, they're actually purchasing. Checking specifically whether a product is labeled with or without DAC is a concrete, worthwhile step before assuming a dosing protocol found online actually applies to the specific product in hand.

Comparing It to Sermorelin

CJC-1295 is frequently compared directly to sermorelin, discussed in its own dedicated guide, since both are GHRH analogs with a similar underlying mechanism. Sermorelin's history as a formerly FDA-approved drug gives it a stronger, more established evidence and regulatory position, while CJC-1295, particularly the extended-release DAC version, remains confined to earlier-stage research and the unregulated research-chemical market, an important distinction despite their mechanistic similarity.